HDAC3 and neoplasm: Consequently, the combination of HDAC3 inhibitors (HDAC3i) and tumor immunotherapy is regarded as a promising new treatment strategy with significant clinical applications and research potential, offering new opportunities to improve the overall prognosis of cancer patients (Figure 3).